novartis ag-reg (NOT:XETRA)
Transactions by NOVARTIS AG-REG (NOT) in the last 6 months
Caribou Biosciences, Inc. announced that it has received undisclosed amount in series A round of equity funding from Novartis AG on January 7, 2015.
Intellia Therapeutics announced that it has received $15 million in its first round of funding from new investors Atlas Venture L.P. and the research arm of Novartis AG. on November 18, 2014. Atlas Venture L.P. invested in the formation of the company.
bioCSL Inc. entered into a definitive agreement to acquire influenza vaccines business from Novartis AG (SWX:NOVN) for approximately $280 million on October 26, 2014. The Novartis influenza vaccines unit will be combined with bioCSL. For the year ended December 31, 2013, influenza vaccines business posted sales of $527 million. The transaction requires regulatory approvals and is expected to close in the second half of 2015. Tim Duncan of Hintons & Associates acted as ...
Raze Therapeutics announced that it has received $24 million in its series A round of funding on October 14, 2014. The transaction included participation from new investors, Atlas Venture L.P., MPM Capital, Merck Serono S.A., Investment Arm, Partners Innovation Fund, Astellas Venture Management LLC, and Novartis AG. As part of the round, Ansbert Gadicke of MPM Capital, Nilesh Kumar of Merck Serono S.A., Investment Arm, Reza Halse of Partners Innovation Fund, Jason Rhodes ...
Atlas Venture L.P.
Merck Serono S.A., Investment Arm
Partners Innovation Fund
|Gilead Sciences Inc||$103.64 USD||-0.55|
|Johnson & Johnson||$102.54 USD||-0.26|
|Merck & Co Inc||$58.54 USD||-0.42|
|Pfizer Inc||$34.34 USD||-0.25|
|Roche Holding AG||SFr.258.80 CHF||-0.20|
|View Industry Companies|